Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mark Vanderkelen
Observed name:
M. Vanderkelen
Institution:
UCB Pharma (Belgium)
Observed institution:
UCB Pharma (Belgium)
OpenAlex ID:
A5025059064
Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database
2018
·
Megan E. B. Clowse
, Angela E. Scheuerle
, et al.
·
Arthritis & Rheumatology
·
198
PDF
Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease
2020
·
Paul D Miller
, Jonathan D Adachi
, et al.
·
Journal of Bone and Mineral Research
·
121
PDF
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study
2024
·
James F. Howard
, Saskia Bresch
, et al.
·
Therapeutic Advances in Neurological Disorders
·
61
Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis
2025
·
Channa Hewamadduma
, Miriam Freimer
, et al.
·
Journal of Neurology
·
11
PDF
Op0297 Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-moderate Chronic Kidney Disease
2020
·
P. Miller
, J. Adachi
, et al.
·
Annals of the Rheumatic Diseases
·
10
PDF
OP0200 Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database
2018
·
M.E.B. Clowse
, A.E. Scheuerle
, et al.
·
Annals of the Rheumatic Diseases
·
7
PDF
P273 Long-term safety, efficacy & self-injection satisfaction with zilucoplan in myasthenia gravis: RAISE-XT interim analysis
2023
·
C. Farmakidis
, M. Leite
, et al.
·
Neuromuscular Disorders
·
2
RAISE-XT: An interim analysis of safety and efficacy in an open-label extension study of zilucoplan in patients with myasthenia gravis (P1-5.007)
2023
·
Miriam Freimer
, M. Isabel Leite
, et al.
·
Neurology
·
2
21086. Reducción Gradual De La Dosis De Corticosteroides Durante El Tratamiento Con Zilucoplán En Pacientes Con Miastenia Gravis Generalizada: Seguimiento a 120 Semanas De Raise-xt
2024
·
R. Juntas Morales
, M. Freimer
, et al.
·
Neurology Perspectives
·
1
Long-term Safety and Efficacy of Zilucoplan in Myasthenia Gravis: Additional Interim Analyses of RAISE-XT (S15.002)
2024
·
James F. Howard
, Miriam Freimer
, et al.
·
Neurology
·
1
2603 Safety and tolerability of zilucoplan in RAISE-XT: a multicenter, open-label extension study in patients with myasthenia gravis
2023
·
Angela Genge
, Yessar Hussain
, et al.
·
BMJ Neurology Open
·
1
PDF
Efficacy and Safety of Zilucoplan for the Treatment of COVID-19 in Hospitalized Patients: Part of the COMMUNITY Platform Trial
2023
·
A. Ako
, S. Glatt
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
1
MON-378 Efficacy and Safety of Romosozumab vs Alendronate Is Similar Across Different Levels of Renal Function Among Postmenopausal Women with Osteoporosis
2020
·
Paul Miller
, Angela M Cheung
, et al.
·
Journal of the Endocrine Society
·
1
PDF
388. Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database
2018
·
Megan E.B. Clowse
, Angela E. Scheuerle
, et al.
·
Pregnancy Hypertension
·
1
28 Characteristics and Outcomes of Prospectively Reported Pregnancies Exposed to Certolizumab Pegol From a Safety Database
2018
·
Anita Afzali
, Megan E.B. Clowse
, et al.
·
Gastroenterology
·
1
21084. Seguridad Y Eficacia a Largo Plazo De Zilucoplán En La Miastenia Gravis Generalizada: Análisis Intermedio De Raise-xt En La Semana 120
2024
·
E. Cortés Vicente
, M. Freimer
, et al.
·
Neurology Perspectives
Long-term safety, efficacy & self-injection satisfaction with zilucoplan in myasthenia gravis: RAISE-XT interim analysis
2023
·
Angela Genge
, M. Isabel Leite
, et al.
·
Journal of the Neurological Sciences
28 Characteristics and Outcomes of Prospectively Reported Pregnancies Exposed to Certolizumab Pegol From a Safety Database
2018
·
Anita Afzali
, Megan E B Clowse
, et al.
·
Inflammatory Bowel Diseases
Variational approach to the matric model
1997
·
Mark Vanderkelen
, Sigurd Schelstraete
, et al.
·
Ghent University Academic Bibliography (Ghent University)
Show more works
View as search
Works count:
19
Citation count:
419
H-index:
6
I10-index:
5
Year
Topic
Type